Cargando…
Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415
PURPOSE: The Expanded Prostate Cancer Index Composite (EPIC) is the most commonly used patient reported outcome (PRO) tool in prostate cancer (PC) clinical trials, but health utilities associated with the different health states assessed with this tool are unknown, limiting our ability to perform co...
Autores principales: | Khairnar, Rahul, Pugh, Stephanie L., Sandler, Howard M., Lee, W. Robert, Villalonga Olives, Ester, Mullins, C. Daniel, Palumbo, Francis B., Bruner, Deborah W., Shaya, Fadia T., Bentzen, Soren M., Shah, Amit B., Malone, Shawn C., Michalski, Jeff M., Dayes, Ian S., Seaward, Samantha A., Albert, Michele, Currey, Adam D., Pisansky, Thomas M., Chen, Yuhchyau, Horwitz, Eric M., DeNittis, Albert S., Feng, Felix Y., Mishra, Mark V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046237/ https://www.ncbi.nlm.nih.gov/pubmed/33852571 http://dx.doi.org/10.1371/journal.pone.0249123 |
Ejemplares similares
-
Serum testosterone changes in patients treated with radiation therapy alone for prostate cancer on NRG oncology RTOG 9408
por: Nichols, R. Charles, et al.
Publicado: (2017) -
Validation of a 22-Gene Genomic Classifier in Patients With Recurrent
Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial
por: Feng, Felix Y., et al.
Publicado: (2021) -
Association of Pretreatment Hippocampal Volume With Neurocognitive Function in Patients Treated With Hippocampal Avoidance Whole Brain Radiation Therapy for Brain Metastases: Secondary Analysis of NRG Oncology/RTOG 0933
por: Abraham, Christopher D., et al.
Publicado: (2021) -
RADI-04. PRETREATMENT VOLUME OF MRI-DETERMINED WHITE MATTER INJURY (WMI) PREDICTS COGNITIVE DECLINE AFTER HIPPOCAMPAL AVOIDANT (HA) WBRT FOR BRAIN METASTASES: SECONDARY ANALYSIS OF NRG ONCOLOGY RTOG 0933
por: Bovi, Joseph, et al.
Publicado: (2019) -
Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial
por: Sartor, Oliver, et al.
Publicado: (2023)